NeoGenomics, Definiens to develop novel assays, 6/17
June 2017—NeoGenomics and Definiens have expanded their alliance to develop and automate the analysis of new biomarker assays for clinical trials and routine clinical testing.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
IHC imaging and analysis system, 6/17
June 2017—Applied Spectral Imaging introduced its HiPath imaging and analysis system, which provides computer-assisted PD-L1 interpretation for research use.
CLSI phlebotomy documents, 6/17
June 2017—The Clinical and Laboratory Standards Institute has published two new phlebotomy documents, “Collection of Diagnostic Venous Blood Specimens (GP41-Ed7)” and “Essential Elements of a Phlebotomy Training Program (GP48-Ed1).”
Circulating cell-free DNA isolation kit, 6/17
June 2017—MagBio Genomics launched its cfKapture 21 kit, a circulating cell-free DNA isolation kit that includes a proprietary reagent designed to prevent post-separation degradation of plasma and ccfDNA fragments for up to 21 days at room temperature. This feature allows laboratories to safely transport and process samples in a longer time frame without the need for extensive cold chain.
FDA clearance for Alere Reader platform, 6/17
June 2017—Alere announced that its Alere Reader, a diagnostic platform with objective result interpretation and connectivity capabilities that can be used to evaluate a variety of lateral flow immunoassay formats and that can be used in point-of-care and laboratory settings, received FDA 510(k) clearance.
ArcherDx, HeliTec strategic partnership, 6/17
June 2017—ArcherDx and precision medicine company HeliTec (Shenzhen, China) announced a strategic partnership to advance NGS-based cancer diagnostic development in China. The partnership will entail co-developing and cross-licensing NGS-based technologies with the goal of registering oncology diagnostic kits with the Chinese Food and Drug Administration.
Drugs of abuse screening reagents, 6/17
June 2017—MedTest announced the commercial launch of urine drugs of abuse screening reagents on the Mindray BA-800M chemistry analyzer for use in clinical laboratories in the United States.
Hematology analyzers, 6/17
June 2017—Horiba has developed two new hematology systems, the Yumizen H1500 and the Yumizen H2500. The CE-marked analyzers offer a throughput of 120 tests per hour for complete blood count, including differential and nucleated red blood cells, and are equipped with a three-dimensional count capable of combining the measurements of cellular complexity, volume, and distribution for each of the leukocyte subpopulations.
FDA-approved sepsis test, 6/16
June 2017—Immunexpress received FDA 510(k) clearance for the use of SeptiCyte Lab as an aid in differentiating infection-positive (sepsis) from infection-negative (SIRS) systemic inflammation in critically ill patients on their first day of ICU admission. It is the first RNA-based clinical diagnostic tool, direct from whole blood, to aid medical providers in the early identification of infection in suspected sepsis patients, according to a company statement.
Siemens gets $8.9 million to develop Zika test, 6/17
June 2017—The U.S. Department of Health and Human Services announced that Siemens Healthineers has been awarded $8.9 million by the Office of the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research and Development Authority to advance the development of a Zika assay for use on the company’s Advia Centaur XPT, Advia Centaur XP, and Advia Centaur CP immunoassay systems for the clinical laboratory.